Johnson & Johnson Total Long Term Liabilities 2010-2024 | JNJ
Johnson & Johnson total long term liabilities from 2010 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
- Johnson & Johnson total long term liabilities for the quarter ending June 30, 2024 were $55.617B, a 8.98% decline year-over-year.
- Johnson & Johnson total long term liabilities for 2023 were $52.502B, a 4.14% decline from 2022.
- Johnson & Johnson total long term liabilities for 2022 were $54.772B, a 12.74% decline from 2021.
- Johnson & Johnson total long term liabilities for 2021 were $62.769B, a 9.19% decline from 2020.
Johnson & Johnson Annual Total Long Term Liabilities
(Millions of US $) |
| 2023 |
$52,502 |
| 2022 |
$54,772 |
| 2021 |
$62,769 |
| 2020 |
$69,123 |
| 2019 |
$62,293 |
| 2018 |
$61,972 |
| 2017 |
$66,606 |
| 2016 |
$44,503 |
| 2015 |
$34,514 |
| 2014 |
$35,575 |
| 2013 |
$32,955 |
| 2012 |
$32,259 |
| 2011 |
$33,753 |
| 2010 |
$23,257 |
| 2009 |
$22,363 |
Johnson & Johnson Quarterly Total Long Term Liabilities
(Millions of US $) |
| 2024-06-30 |
$55,617 |
| 2024-03-31 |
$53,221 |
| 2023-12-31 |
$52,502 |
| 2023-09-30 |
$50,463 |
| 2023-06-30 |
$61,107 |
| 2023-03-31 |
$64,727 |
| 2022-12-31 |
$54,772 |
| 2022-09-30 |
$54,982 |
| 2022-06-30 |
$56,546 |
| 2022-03-31 |
$60,256 |
| 2021-12-31 |
$62,769 |
| 2021-09-30 |
$64,395 |
| 2021-06-30 |
$68,139 |
| 2021-03-31 |
$65,791 |
| 2020-12-31 |
$69,123 |
| 2020-09-30 |
$67,373 |
| 2020-06-30 |
$58,630 |
| 2020-03-31 |
$60,034 |
| 2019-12-31 |
$62,293 |
| 2019-09-30 |
$62,149 |
| 2019-06-30 |
$62,979 |
| 2019-03-31 |
$61,961 |
| 2018-12-31 |
$61,972 |
| 2018-09-30 |
$63,640 |
| 2018-06-30 |
$64,988 |
| 2018-03-31 |
$66,289 |
| 2017-12-31 |
$66,606 |
| 2017-09-30 |
$49,873 |
| 2017-06-30 |
$52,013 |
| 2017-03-31 |
$49,458 |
| 2016-12-31 |
$44,503 |
| 2016-09-30 |
$44,370 |
| 2016-06-30 |
$45,805 |
| 2016-03-31 |
$41,450 |
| 2015-12-31 |
$34,514 |
| 2015-09-30 |
$36,452 |
| 2015-06-30 |
$36,393 |
| 2015-03-31 |
$36,876 |
| 2014-12-31 |
$35,575 |
| 2014-09-30 |
$32,524 |
| 2014-06-30 |
$32,793 |
| 2014-03-31 |
$32,908 |
| 2013-12-31 |
$32,955 |
| 2013-09-30 |
$31,294 |
| 2013-06-30 |
$30,893 |
| 2013-03-31 |
$32,157 |
| 2012-12-31 |
$32,259 |
| 2012-09-30 |
$31,255 |
| 2012-06-30 |
$31,468 |
| 2012-03-31 |
$33,630 |
| 2011-12-31 |
$33,753 |
| 2011-09-30 |
$28,608 |
| 2011-06-30 |
$28,997 |
| 2011-03-31 |
$24,276 |
| 2010-12-31 |
$23,257 |
| 2010-09-30 |
$23,542 |
| 2010-06-30 |
$22,285 |
| 2010-03-31 |
$22,028 |
| 2009-12-31 |
$22,363 |
| 2009-09-30 |
$21,929 |
| 2009-06-30 |
$21,305 |
| 2009-03-31 |
$20,984 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$399.964B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
